GSK to acquire 35Pharma in $950M deal for cardiovascular drug
Source: BioPharma Dive - Latest News
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.